Korsten, Peter

[["dc.bibliographiccitation.artnumber","208"],["dc.bibliographiccitation.journal","Frontiers in Medicine"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Müller, Gerhard A."],["dc.contributor.author","Rademacher, Jan-Gerd"],["dc.contributor.author","Zeisberg, Michael"],["dc.contributor.author","Tampe, Björn"],["dc.date.accessioned","2019-09-24T08:03:09Z"],["dc.date.available","2019-09-24T08:03:09Z"],["dc.date.issued","2019"],["dc.description.abstract","Raynaud's phenomenon (RP) is almost universally present in patients with Systemic Sclerosis (SSc). RP represents a generalized vasculopathy and potentially lead to digital ulcers (DU), which may be complicated by superinfection, tissue necrosis, and limb loss. We report the analysis of an extracorporeal procedure in a 36-year-old female patient with diffuse SSc with refractory RP and DU despite treatment with diltiazem, candesartan, sildenafil, and intravenous iloprost. We performed rheopheresis (RheoP), a variant of double-filtration plasmapheresis, as a potential new treatment option for refractory patients despite optimal medical therapy. We performed two RheoP per week every 4 weeks for a total of 3 months. Clinical improvement in DU healing occurred with no adverse events directly related to the treatment. While there was no reduction in the number of Raynaud attacks with RheoP, a significant reduction of the duration of attacks from a median of 15 (5–45, 95% CI 10–15) to 7 (3–30, 95% CI 6–10) minutes with an improvement of the Raynaud Condition Score (RCS) improved from 4 to 2. In conclusion, RheoP is a feasible and potentially beneficial treatment modality in patients with refractory RP and DU. We propose that RheoP should be investigated in a larger number of patients in a clinical trial setting."],["dc.identifier.doi","10.3389/fmed.2019.00208"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16392"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62449"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2296-858X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Rheopheresis for Digital Ulcers and Raynaud's Phenomenon in Systemic Sclerosis Refractory to Conventional Treatments"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","2072143"],["dc.bibliographiccitation.journal","Human Vaccines & Immunotherapeutics"],["dc.contributor.author","Plüß, Marlene"],["dc.contributor.author","Piantoni, Silvia"],["dc.contributor.author","Tampe, Björn"],["dc.contributor.author","Kim, Alfred H. J."],["dc.contributor.author","Korsten, Peter"],["dc.date.accessioned","2022-06-01T09:39:18Z"],["dc.date.available","2022-06-01T09:39:18Z"],["dc.date.issued","2022"],["dc.description.abstract","In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1λ antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Recently, the superiority of the addition of BEL to SoC was also demonstrated in LN. In this review, we provide a comprehensive overview of the study landscape, available therapeutic options for SLE (focusing on BEL in renal and non-renal SLE), and new perspectives in the treatment field of this disease. A personalized treatment approach will likely become available with the advent of novel therapeutic agents for SLE and LN."],["dc.identifier.doi","10.1080/21645515.2022.2072143"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108436"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2164-554X"],["dc.relation.issn","2164-5515"],["dc.rights.uri","http://creativecommons.org/licenses/by-nc-nd/4.0/"],["dc.title","Belimumab for systemic lupus erythematosus – Focus on lupus nephritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1057"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Zeitschrift für Rheumatologie"],["dc.bibliographiccitation.lastpage","1066"],["dc.bibliographiccitation.volume","79"],["dc.contributor.author","Juche, A."],["dc.contributor.author","Siegert, E."],["dc.contributor.author","Mueller-Ladner, U."],["dc.contributor.author","Riemekasten, G."],["dc.contributor.author","Günther, C."],["dc.contributor.author","Kötter, I."],["dc.contributor.author","Henes, J."],["dc.contributor.author","Blank, N."],["dc.contributor.author","Voll, R. E."],["dc.contributor.author","Ehrchen, J."],["dc.contributor.author","Schmalzing, M."],["dc.contributor.author","Susok, L."],["dc.contributor.author","Schmeiser, T."],["dc.contributor.author","Sunderkoetter, C."],["dc.contributor.author","Distler, J."],["dc.contributor.author","Worm, M."],["dc.contributor.author","Kreuter, A."],["dc.contributor.author","Horváth, O. N."],["dc.contributor.author","Schön, M. P."],["dc.contributor.author","Korsten, P."],["dc.contributor.author","Zeidler, G."],["dc.contributor.author","Pfeiffer, C."],["dc.contributor.author","Krieg, T."],["dc.contributor.author","Hunzelmann, N."],["dc.contributor.author","Moinzadeh, P."],["dc.date.accessioned","2020-12-10T14:10:25Z"],["dc.date.available","2020-12-10T14:10:25Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00393-019-00743-9"],["dc.identifier.eissn","1435-1250"],["dc.identifier.issn","0340-1855"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70754"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Versorgungsrealität der stationären vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen Durchblutungsstörungen bei systemischer Sklerose in Deutschland"],["dc.title.alternative","Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2682"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Hakroush, Samy"],["dc.contributor.author","Tampe, Désirée"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Tampe, Björn"],["dc.date.accessioned","2021-08-12T07:45:59Z"],["dc.date.available","2021-08-12T07:45:59Z"],["dc.date.issued","2021"],["dc.description.abstract","Background: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small vessel vasculitis, most frequently presenting as microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA). Acute tubular injury with the presence of tubulitis was previously reported to be of prognostic value in ANCA glomerulonephritis (GN). In particular, distinct tubular injury lesions were associated with the deterioration of kidney function at AAV disease onset, as well as renal resistance to treatment, and higher risk of progression to composite outcome in patients with AAV. To expand our knowledge regarding distinct tubular lesions in AAV, we aimed to describe acute tubular injury patterns in association with glomerular lesions in ANCA GN by systematic histological scoring. Methods: A total number of 48 renal biopsies with confirmed renal involvement of AAV admitted to the University Medical Center Göttingen from 2015 to 2020 were retrospectively examined. By systematic scoring of tubular injury lesions, the association between clinical parameters, laboratory markers, and histopathological findings was explored. Results: We have shown that cellular casts in renal biopsies were frequently observed in the majority of cases with ANCA GN. Furthermore, we showed that tubular epithelial simplification with dilatation correlated with MPA and MPO subtypes, C3c hypocomplementemia, severe renal involvement, and uACR. Red blood cell (RBC) casts were associated with increased levels of C-reactive protein (CRP), leukocyturia, and hematuria. Finally, we found that hyaline casts were associated with an increased fraction of glomeruli with global glomerular sclerosis. Conclusions: Acute tubular injury patterns were correlated with active ANCA GN, whereas tubular injury lesions reflecting the later stages of kidney disease correlated with chronic glomerular lesions. These results suggest an interplay between different renal compartments."],["dc.description.abstract","Background: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small vessel vasculitis, most frequently presenting as microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA). Acute tubular injury with the presence of tubulitis was previously reported to be of prognostic value in ANCA glomerulonephritis (GN). In particular, distinct tubular injury lesions were associated with the deterioration of kidney function at AAV disease onset, as well as renal resistance to treatment, and higher risk of progression to composite outcome in patients with AAV. To expand our knowledge regarding distinct tubular lesions in AAV, we aimed to describe acute tubular injury patterns in association with glomerular lesions in ANCA GN by systematic histological scoring. Methods: A total number of 48 renal biopsies with confirmed renal involvement of AAV admitted to the University Medical Center Göttingen from 2015 to 2020 were retrospectively examined. By systematic scoring of tubular injury lesions, the association between clinical parameters, laboratory markers, and histopathological findings was explored. Results: We have shown that cellular casts in renal biopsies were frequently observed in the majority of cases with ANCA GN. Furthermore, we showed that tubular epithelial simplification with dilatation correlated with MPA and MPO subtypes, C3c hypocomplementemia, severe renal involvement, and uACR. Red blood cell (RBC) casts were associated with increased levels of C-reactive protein (CRP), leukocyturia, and hematuria. Finally, we found that hyaline casts were associated with an increased fraction of glomeruli with global glomerular sclerosis. Conclusions: Acute tubular injury patterns were correlated with active ANCA GN, whereas tubular injury lesions reflecting the later stages of kidney disease correlated with chronic glomerular lesions. These results suggest an interplay between different renal compartments."],["dc.description.sponsorship","Georg-August-Universität Göttingen"],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.3390/jcm10122682"],["dc.identifier.pii","jcm10122682"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88590"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Systematic Scoring of Tubular Injury Patterns Reveals Interplay between Distinct Tubular and Glomerular Lesions in ANCA-Associated Glomerulonephritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","290"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Zeitschrift für Rheumatologie"],["dc.bibliographiccitation.lastpage","299"],["dc.bibliographiccitation.volume","74"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Mueller, Georg Anton"],["dc.date.accessioned","2018-11-07T09:57:36Z"],["dc.date.available","2018-11-07T09:57:36Z"],["dc.date.issued","2015"],["dc.description.abstract","Interstitial nephritis is responsible for about 12% of end-stage renal disease in Germany. It comprises an etiologically heterogenous group of inflammatory renal disorders which primarily affect the renal interstitium and tubuli. Drugs, predominantly antibiotics, nonsteroidal anti-inflammatory drugs and proton pump inhibitors are causative in the majority of cases. Rheumatic diseases frequently affect the kidneys, either the glomeruli or the interstitial tissues. Inflammatory interstitial processes can be accompanied by complex functional tubular disorders. This review gives an overview about clinical and laboratory findings of interstitial nephritis in the context of rheumatic diseases. Sarcoidosis, tubulointerstitial nephritis and uveitis (TINU) syndrome, primary Sjogren's syndrome, and IgG4-related disease often show an interstitial nephritis when the kidneys are affected. Other diseases, such as systemic lupus erythematosus, systemic sclerosis, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, and granulomatosis with polyangiitis are more rarely associated with predominant interstitial nephritis. Glucocorticoids are the mainstay of therapy for most cases; in refractory cases or when side effects occur, second-line immunosuppressants such as mycophenolate mofetil, azathioprine and others, rarely biologics, can be used."],["dc.identifier.doi","10.1007/s00393-014-1482-0"],["dc.identifier.isi","000355606600004"],["dc.identifier.pmid","25962450"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37197"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1435-1250"],["dc.relation.issn","0340-1855"],["dc.title","Interstitial nephritis in rheumatic diseases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","annrheumdis-2020-218491"],["dc.bibliographiccitation.journal","Annals of the Rheumatic Diseases"],["dc.contributor.author","Hakroush, Samy"],["dc.contributor.author","Franz, Jonas"],["dc.contributor.author","Larsen, Jörg"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Winkler, Martin Sebastian"],["dc.contributor.author","Tampe, Björn"],["dc.date.accessioned","2021-06-01T10:47:36Z"],["dc.date.available","2021-06-01T10:47:36Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1136/annrheumdis-2020-218491"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85655"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1468-2060"],["dc.relation.issn","0003-4967"],["dc.title","Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","349"],["dc.bibliographiccitation.journal","Drug Design Development and Therapy"],["dc.bibliographiccitation.lastpage","364"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Shetty, Anjali"],["dc.contributor.author","Hanson, Rebekah"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Shawagfeh, Munir"],["dc.contributor.author","Arami, Shiva"],["dc.contributor.author","Volkov, Suncica"],["dc.contributor.author","Vila, Olga"],["dc.contributor.author","Swedler, William"],["dc.contributor.author","Shunaigat, Abdel Naser"],["dc.contributor.author","Smadi, Sameer"],["dc.contributor.author","Sawaqed, Ray"],["dc.contributor.author","Perkins, David"],["dc.contributor.author","Shahrara, Shiva"],["dc.contributor.author","Sweiss, Nadera J."],["dc.date.accessioned","2018-11-07T09:46:20Z"],["dc.date.available","2018-11-07T09:46:20Z"],["dc.date.issued","2014"],["dc.description.abstract","Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by joint pain, swelling, stiffness, and progressive destruction of the small joints of the hands and feet. Treatment of RA has improved over the past decade. With multiple cytokines well-known now to play a role in the pathogenesis of RA, including tumor necrosis factor alpha, interleukin (IL)-1 beta, and IL-6, many targeted biological treatments against these cytokines have emerged, changing the treatment of this disease. Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody against the IL-6 receptor and has been approved in many countries, including the United States, for the treatment of moderate to severe RA in patients who have not adequately responded to one or more disease-modifying antirheumatic drugs (DMARDs) or cannot tolerate other approved drug classes for RA. The aim of this review is to discuss the role of IL-6 in RA, and to provide an overview of the mode of action, pharmacokinetics, and safety of TCZ. Furthermore, efficacy studies of TCZ as both monotherapy and combination therapy will be evaluated. There have been several important clinical trials evaluating the efficacy and safety of TCZ in RA patients; this review summarizes this data from 14 key trials with emphasis on Phase III trials. Review of these trials provides strong evidence that its use, both as monotherapy and in combination with methotrexate or other DMARDs, is an effective treatment in reducing the signs and symptoms of RA. TCZ showed tolerable safety but care is required for its use since there are some important safety concerns including elevated liver enzymes, elevated low-density lipoprotein, infections, and gastrointestinal perforations. Additionally, given the efficacy of TCZ in the treatment of RA, this review discusses how TCZ may be beneficial in the treatment of other autoimmune diseases, spinal disease, cardiovascular disease, organ transplantation, and malignancies where elevated levels of IL-6 may play a role in the pathogenesis of these diseases."],["dc.identifier.doi","10.2147/DDDT.S41437"],["dc.identifier.isi","000333537100001"],["dc.identifier.pmid","24729685"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15281"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34847"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1177-8881"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tocilizumab in the treatment of rheumatoid arthritis and beyond"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Chest"],["dc.bibliographiccitation.lastpage","1308"],["dc.bibliographiccitation.volume","159"],["dc.contributor.author","Sweiss, Nadera J."],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Baughman, Robert P."],["dc.contributor.author","Culver, Daniel A."],["dc.contributor.author","Judson, Marc A."],["dc.date.accessioned","2021-04-14T08:29:02Z"],["dc.date.available","2021-04-14T08:29:02Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1016/j.chest.2020.10.005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82773"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0012-3692"],["dc.title","Response"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Rheumatology"],["dc.bibliographiccitation.volume","56"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Bahlmann, Dirk"],["dc.contributor.author","Patschan, Susann Andrea"],["dc.date.accessioned","2018-11-07T10:22:05Z"],["dc.date.available","2018-11-07T10:22:05Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1093/rheumatology/kex007"],["dc.identifier.isi","000404610700010"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42214"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1462-0332"],["dc.relation.issn","1462-0324"],["dc.title","Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2071"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Rheumatology"],["dc.bibliographiccitation.lastpage","2073"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Seitz, Cornelia S"],["dc.contributor.author","Sahlmann, Carsten O"],["dc.contributor.author","Schmidt, Jens"],["dc.date.accessioned","2020-12-10T18:19:41Z"],["dc.date.available","2020-12-10T18:19:41Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1093/rheumatology/kez313"],["dc.identifier.eissn","1462-0332"],["dc.identifier.issn","1462-0324"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75335"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]